

## AMENDMENT

### Listing of Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

1.-47. (Canceled)

48. (Previously Presented) A method of eliciting an immune response comprising:  
obtaining a viral particle comprising a reverse transcriptase that has been inactivated by  
binding said reverse transcriptase with one or more azido-labeled compounds and  
then irradiating said reverse transcriptase; and  
administering the viral particle to a subject, wherein an immune response is elicited in the  
subject.

49.-56. (Canceled)

57. (New) The method of claim 48, wherein said azido-labeled compound is azido  
dipyridodiazepinona or *N*-[4-chloro-3-(3-methyl-2-butenyloxy)phenyl]-2-methyl-3-  
furanocarbothiamide.

58. (New) The method of claim 48, wherein said azido-labeled compound is *N*-[4-chloro-3-  
(3-methyl-2-butenyloxy)phenyl]-2-methyl-3-furanocarbothiamide.

59. (New) The method of claim 48, wherein the irradiation is with UV light.

60. (New) The method of claim 48, wherein the viral particle is an HIV particle.

61. (New) The method of claim 60, wherein said HIV particle is HIV-1.

62. (New) The method of claim 61, wherein said HIV-1 is Group M or Group O.

63. (New) The method of claim 62, wherein said Group M are selected from the group consisting of clade A, clade B, clade C, clade D, clade E, clade F, clade G, clade H, and clade I.
64. (New) The method of claim 62, wherein said Group M particles are clade B particles.